CTRI/2023/10/059260
Not yet recruiting
未知
Validation of PREDICT V 2.2 Breast Cancer Prognostication Tool In Patients attending a Tertiary Cancer Care Centre In Kerala. - NI
I0 sites0 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- I
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Non metastatic invasive carcinoma of breast
- •after primary breast conservation surgery or modified radical mastectomy
- •Breast cancer patients who were diagnosed and treated at Caritas cancer institute between 1 st January 2015 and 31 st December2019
Exclusion Criteria
- •Patients with bilateral breast cancer/ ductal carcinoma insitu/ lobular carcinoma in situ
- •Patients who underwent neoadjuvant chemotherapy or endocrine therapy
- •Patient who has breast cancer as second primary
- •Patients with incomplete medicalrecords or missing data necessary for PREDICT tool calculation
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Clinical performance study of breast cancer prognostic diagnosticsGenesWell™ BCT in Korean patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancerKCT0004263Samsung Medical Center500
Not yet recruiting
Not Applicable
Studying the risk factors for breast cancer in Indian women.ÂCTRI/2019/10/021652Tata Memorial Centre
Recruiting
Phase 2
Pre-operative phase II trial for breast cancer with nivolumab in combination with novel IO (BELLINI trial)NL-OMON54814ederlands Kanker Instituut90
Active, not recruiting
Phase 1
Pre-operative study for breast cancer with nivolumab in combination with other therapyMedDRA version: 21.1Level: LLTClassification code 10006188Term: Breast cancer female NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10006194Term: Breast cancer NOS stage ISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10006195Term: Breast cancer NOS stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10006196Term: Breast cancer NOS stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-004188-30-NLKI-AV90
Completed
Not Applicable
Validation study of the prognostic and predictive value of TP53 signature for breast cancer Collateral researchJPRN-UMIN000042055Japan Agency for Medical Research and Development107